Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-labelled study to evaluate the efficacy and safety of
camrelizumab combined with apatinib mesylate in the induction treatment of patients with
locally advanced head and neck squamous cell carcinoma who were judged surgically
unresectable or appropriate for non-surgical definitive therapy. The objective response rate
(ORR) and safety will be evaluated as the primary endpoints, the 2-year overall survival (OS)
rate and progression free survival (PFS) rate will be the second endpoints.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University